In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis
暂无分享,去创建一个
S. Tanaka | J. Steenbergen | Judith Steenbergen | S. Ken Tanaka | Lynda L. Miller | Stephanie A. Halasohoris | Jeremy R. Hershfield | L. Miller
[1] M. Albert,et al. High prevalence of ciprofloxacin resistance amongst strains of Neisseria gonorrhoeae isolated from commercial sex workers in Bangladesh. , 1998, The Journal of antimicrobial chemotherapy.
[2] J. Hartings,et al. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. , 2004, Journal of pharmacological and toxicological methods.
[3] Tanja Popovic,et al. Investigation of Bioterrorism-Related Anthrax, United States, 2001: Epidemiologic Findings , 2002, Emerging infectious diseases.
[4] P. Worsham,et al. In Vitro Antibiotic Susceptibilities of Yersinia pestis Determined by Broth Microdilution following CLSI Methods , 2015, Antimicrobial Agents and Chemotherapy.
[5] Shay Weiss,et al. Lessons to be Learned from Recent Biosafety Incidents in the United States. , 2015, The Israel Medical Association journal : IMAJ.
[6] S. Levy,et al. Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline , 2015, Antimicrobial Agents and Chemotherapy.
[7] X. Cui,et al. Anthrax infection. , 2011, American journal of respiratory and critical care medicine.
[8] H. Schweizer. Mechanisms of antibiotic resistance in Burkholderia pseudomallei: implications for treatment of melioidosis. , 2012, Future microbiology.
[9] S. Levy,et al. In Vitro and In Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline , 2013, Antimicrobial Agents and Chemotherapy.
[10] F. Romesberg,et al. Origins of Yersinia pestis Sensitivity to the Arylomycin Antibiotics and the Inhibition of Type I Signal Peptidase , 2015, Antimicrobial Agents and Chemotherapy.
[11] K. R. May. The collison nebulizer: Description, performance and application , 1973 .
[12] J. Kaur,et al. Forensic Odontology in the Management of Bioterrorism , 2013 .
[13] M. Huband,et al. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). , 2018, Diagnostic microbiology and infectious disease.
[14] S. Levy,et al. Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline , 2013, Antimicrobial Agents and Chemotherapy.
[15] J. Petersen,et al. Comparative review of Francisella tularensis and Francisella novicida , 2014, Front. Cell. Infect. Microbiol..
[16] A. Goel. Anthrax: A disease of biowarfare and public health importance. , 2015, World journal of clinical cases.
[17] Theresa L. Smith,et al. Centers for Disease Control and Prevention Expert Panel Meetings on Prevention and Treatment of Anthrax in Adults , 2014, Emerging infectious diseases.
[18] M. Huband,et al. Activity of omadacycline tested against Enterobacteriaceae causing urinary tract infections from a global surveillance program (2014). , 2018, Diagnostic microbiology and infectious disease.
[19] Philip K. Russell,et al. Tularemia as a biological weapon: medical and public health management. , 2001, JAMA.
[20] Philip K. Russell,et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 2000, JAMA.
[21] Gina Pugliese,et al. Anthrax as a Biological Weapon: Medical and Public Health Management , 1999 .
[22] Laura A. Muruato,et al. Recent Advances in Burkholderia mallei and B. pseudomallei Research , 2015, Current Tropical Medicine Reports.
[23] Mary Jane Ferraro,et al. Performance standards for antimicrobial susceptibility testing : twelfth informational supplement , 2002 .
[24] J. Ezzell,et al. Antibiotic Treatment of Experimental Pneumonic Plague in Mice , 1998, Antimicrobial Agents and Chemotherapy.
[25] R. Doi,et al. The stability of messenger ribonucleic acid during sporulation in Bacillus subtilis. , 1971, The Journal of biological chemistry.
[26] Mary Jane Ferraro,et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .
[27] B. Currie. Melioidosis: Evolving Concepts in Epidemiology, Pathogenesis, and Treatment , 2015, Seminars in Respiratory and Critical Care Medicine.
[28] P. Wayne. PERFORMANCE STANDARDS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING, NINTH INFORMATIONAL SUPPLEMENT , 2008 .
[29] A. C. Guyton,et al. Measurement of the respiratory volumes of laboratory animals. , 1947, The American journal of physiology.
[30] Douglas K Owens,et al. Systematic Review: A Century of Inhalational Anthrax Cases from 1900 to 2005 , 2006, Annals of Internal Medicine.
[31] W. J. Novick. Development of in vitro susceptibility testing criteria and quality control parameters , 1989 .
[32] Scott R. Lillibridge,et al. Public Health Assessment of Potential Biological Terrorism Agents , 2002, Emerging infectious diseases.
[33] B. Ivins,et al. Determination of Antibiotic Efficacy against Bacillus anthracis in a Mouse Aerosol Challenge Model , 2007, Antimicrobial Agents and Chemotherapy.
[34] Philip K. Russell,et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. , 1999, JAMA.